SBIR/STTR Research Award

Development of human embryonic cell lines

Award identifier 7dca61610391614400c8ca9550c73b4a3c4fd7fa3c77e9bb358ce2e65b365c4bAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$644,389

Program and phase

SBIR · Phase I

Award year

2003

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ViaCyte, Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
QKEMQKGYSSL1
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): The goal of this proposed project is to establish the infrastructure to develop, characterize, and share useful human embryonic stem cell lines from the group of derivations designated CY12, CY30, CY40, CY51, CY81, CY82, CY91, CY92, and CY10 on the NIH Human Embryonic Stem Cell Registry. These cells meet the federal criteria for funding. The cells are at a very early stage of development. They were frozen at early passage, and exist now as frozen specimens; there is one vial of CY12 and of CY92, but there are at least two, and as many as 6 frozen vials of the others. The cells have been passaged up to 5 times, and have given rise to alkaline phosphatase-positive colonies. Since the cells are part of a limited resource, the first aim is a cautious approach to developing conditions that allow survival of the cells. The other 3 aims are to characterize the cells and provide them to researchers. Specific Aim 1: Establish culture conditions for recovery, expansion, and production of clonal lines of early stage human derivations. Using established hES cell lines, we will evaluate and improve if necessary the co-culture methods used for the initial derivation of the cells. Specific Aim 2: Establish cell lines from early stage human derivations and characterize them by standard criteria. We will use the methods developed in Aim l to recover cells from the derivations, and use the standard criteria for identifying the cells as ES cells. Specific Aim 3: Genotype and phenotype the hES cell lines. We will use microsatellite genotyping and a simple SNP screen to obtain genetic information about the cells. We will phenotype the cells by limited microarray analysis similar to that done for mouse ES cells, and confirm and extend the microarray results with quantitative RTPCR. Specific Aim 4: Expand hES cell lines and provide them to other laboratories. We plan to distribute the cells to other researchers and share our expertise in order to help in establishing uniform standards.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

3 SBIR/STTR records share this UEI (2000–2017). Reported award amounts total $1,698,595. Reported amounts are not federal obligations.

Phases: Phase I, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.